Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising ...

The U.K. is asking patients whose pancreas became dangerously inflamed after taking obesity drugs like Wegovy and Zepbound to ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

Of the 102,166 GLP-1s analyzed, 94% had some form of commercial insurance, yet cost-saving options were still widely overlooked.

Mounjaro and Zepbound face strong competition from Novo Nordisk’s semaglutide medicines, Ozempic for diabetes and Wegovy for obesity. Several companies like Amgen AMGN and Viking Therapeutics VKTX are ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...